Protein Design Labs Discontinues Daclizumab Development For Colitis; Asthma Is “Top Priority” Indication

The firm is discontinuing development for ulcerative colitis in light of a Phase II study that failed to meet the primary efficacy endpoint: remission at week eight. Follow-on Phase II studies in asthma and multiple sclerosis are expected to begin by the first quarter of 2005.